A 54-year-old female presents to an outpatient nephrology clinic for rapid-onset swelling in her lower extremities and dark urine. She also reports progressive joint stiffness in her hands and knees over the past month, accompanied by a new, non-itchy rash on her shins. Her past medical history is significant for a brief period of intravenous drug use in her early twenties, but she has not sought medical care in over a decade. Her vital signs include a blood pressure of 152/94 mmHg. Physical examination demonstrates 2+ pitting edema to the knees and scattered, palpable purpuric lesions across both lower legs.
Laboratory testing reveals:
Serum creatinine: 1.9 mg/dL (Baseline unknown)
Urinalysis: 3+ protein, 20-30 red blood cells/hpf, dysmorphic red cells present
Rheumatoid factor: 420 IU/mL (Normal: < 15 IU/mL)
Complement C3: 92 mg/dL (Normal: 80-160 mg/dL)
Complement C4: 6 mg/dL (Normal: 15-45 mg/dL)
Hepatitis C virus RNA: 2.1 x 10^6 IU/mL
Which of the following best describes the fundamental immunopathologic mechanism driving this patient's current presentation?
- AMesangial deposition of aberrantly glycosylated IgA1-containing immune complexes
- BIgG autoantibody-mediated stabilization of the alternative complement pathway C3bBb convertase
- Formation of immune complexes by IgM autoantibodies binding to the Fc region of endogenous IgGCevap
- DProduction of IgG autoantibodies targeting myeloperoxidase within neutrophil primary granules
- EDirect binding of autoantibodies to the non-collagenous domain of type IV collagen in the basement membrane